

Metabomed, a cancer metabolism company, has secured $12.5 million in funding. Yonjin Venture led the round with participation from return backers M Ventures, Pfizer Ventures, Pontifax Venture Fund, Boehringer Ingelheim Venture Fund and Arkin Bio Ventures.
Source: Press Release